A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

Phase 1 Not yet recruiting 48 enrolled Addpharma Inc.

RandomizedCrossoverOpen-labelTreatment

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.

Evaluation	Drug	Modality	Dose	Route
Subject	AD-120	Unknown	—	Oral
Subject	AD-120A	Unknown	—	Oral